natgillin/translations-raw huggingface dataset:
Hepatic insufficiency:
Okvarjeno jetrno delovanje
Hepatic insufficiency:
Okvarjeno jetrno delovanje:
Hepatic laboratory testing including direct bilirubin levels should be performed at baseline, during the first 4 weeks of starting treatment and as clinically indicated thereafter.
na začetku, v prvih 4 tednih po začetku zdravljenja in pozneje kot je klinično indicirano je treba
Hepatic metabolism of anidulafungin has not been observed.
Presnove anidulafungina v jetrih niso zabeležili.
Hepatic necrosis
Nekroza jeter
Hepatic neoplasm
maligne jetrne novotvorbe
Hepatic or renal impairment
Okvare ledvic ali jeter
Hepatic or renal impairment:
Jetrna ali ledvična okvara:
Hepatic or renal impairment:
Okvara jeter ali ledvic:
Hepatic pain
Bolečina v jetrih
Hepatic pain, gammaglutamyl transferase increased.
bolečina v jetrih, zvišana gama-glutamiltransferaza
Hepatic reactions
Bolezni jeter
Hepatic Risk Management Guide, Patient Card
Vodnik za obvladovanje tveganj za jetra, Opozorilna kartica za bolnika
Hepatic safety
Varnost za jetra
Hepatic steatosis and risk of progressive liver disease
Jetrna steatoza in tveganje napredujoče jetrne bolezni
Hepatic steatosis Hepatotoxicity Hepatomegaly
jetrna steatoza, hepatotoksičnost, hepatomegalija
Hepatic steatosis is a risk factor for progressive liver disease including steatohepatitis and cirrhosis.
Jetrna steatoza je dejavnik tveganja za napredujočo jetrno bolezen, vključno s steatohepatitisom in cirozo.
Hepatic steatosis, hepatomegaly, cholangitis, hyperbilirubinemia
hepatična statoza, hepatomegalija, holangitis, hiperbilirubinemija
Hepatic Toxicity
Jetrna toksičnost
Hepatic toxicity (ALT or AST elevation), neutropenia
Hepatotoksičnost (povišana vrednost ALT ali AST), nevtropenija
Hepatic Toxicity (ALT, AST)
Jetrna toksičnost (ALT, AST)
Hepatic transaminase abnormalities
Nenormalnosti jetrne transaminaze
Hepatic transaminase and bilirubin levels should be investigated before the initiation of treatment with Ofev, and periodically thereafter (e.g. at each patient visit) or as clinically indicated.
Pred uvedbo zdravljenja z zdravilom Ofev in nato periodično (npr. ob vsakem obisku bolnika) ali kot je klinično indicirano je treba določiti ravni jetrnih aminotransferaz in bilirubina.
Hepatic transaminases increased, Weight increased, Total bilirubin increased*
zvišanje jetrnih transaminaz, zvečanje telesne mase, zvišanje celotnega bilirubina
Hepatic transplant
Jetrni presadek
Hepatic transplant patients were followed for at least 1 year, but less than 3 years.
Bolnikom z jetrnim presadkom so sledili vsaj eno leto, vendar pa manj kot tri leta.
Hepatically impaired patients:
Bolnice z okvarami jeter:
Hepatitis
hepatitis,
Hepatitis
Hiperhidroza
Hepatitis
makulopapulozni izpuščaj
hepatitis
odpoved jeter, hepatitis
Hepatitis
vnetje jeter (hepatitis)
hepatitis (auto-immune) (may cause yellowing of the skin and eyes, dark coloured urine) difficulty of coordinating muscles
hepatitis (avtoimunski) (lahko povzroči porumenelost kože in oči, temno obarvan urin); težave s koordinacijo mišic.
hepatitis (autoimmune hepatitis and drug induced liver injury)
hepatitis (avtoimunski hepatitis in z zdravilom izzvana poškodba jeter)
Hepatitis (including
Hepatitis (vključno s
hepatitis (including hepatic enzyme increased)
hepatitis (vključno s povečanimi vrednostmi jetrnih encimov)
Hepatitis (including hepatocellula r, cholestatic or mixed liver injury)11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro
Hepatitis (including hepatocellular,
Hepatitis (vključno
Hepatitis (including hepatocellular, cholestatic or mixed
Hepatitis (vključno
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
hepatitis (vključno s hepatocelul arno, holestatsko ali mešano okvaro jeter)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
hepatitis (vključno s hepatocelular no, holestatsko ali mešano okvaro jeter)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
hepatocelularno, holestatsko ali mešano okvaro jeter)11
Hepatitis (including increased AST, ALT, GGT), blood bilirubin increased (including jaundice)
hepatitis (vključno z zvišanjem AST, ALT, GGT), zvišanje bilirubina v krvi
Hepatitis (including increased AST, ALT, GGT), blood bilirubin increased (including jaundice)
hepatitis (vključno z zvišanjem AST, ALT, GGT), zvišanje bilirubina v krvi (vključno z zlatenico)
hepatitis (inflamation of the liver), jaundice (yellow of the skin or eyes)
hepatitis (vnetje jeter), zlatenica (rumeno obarvanje kože ali oči)
Hepatitis (inflamed liver)
hepatitis (vnetje jeter)
Hepatitis (inflammation of the liver)
Hepatitis (vnetje jeter)
hepatitis (inflammation of the liver) anaphylactic shock (severe allergic reaction)
hepatitis (vnetje jeter) anafilaktični šok (huda alergijska reakcija)
hepatitis (inflammation of the liver) itching
hepatitis (vnetje jeter) srbenje
Hepatitis (reversible upon discontinuation of the medicinal product) Abnormal liver function tests (reversible upon discontinuation of the medicinal product)
hepatitis (reverzibilen po prekinitvi uporabe zdravila) nenormalne vrednosti testov jetrne funkcije (reverzibilne po prekinitvi uporabe zdravila)
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Cepivo proti hepatitisu A, inaktivirano, in hepatitisu B, rekombinantno (HAB), adsorbirano
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Cepivo proti hepatitisu A, inaktivirano, in hepatitisu B, rekombinantno (HAB), adsorbirano
Hepatitis A virus (inactivated)1,2 360 ELISA Units
Virus hepatitisa A (inaktivirani)1,2 360 ELISA enot
Hepatitis A virus (inactivated)1,2 720 ELISA Units
Virus hepatitisa A (inaktivirani)1,2 720 ELISA enot
Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver.
Hepatitis A: Hepatitis A je nalezljiva bolezen, ki prizadene jetra.
Hepatitis A: Infection with the hepatitis A virus may cause the liver to become swollen (inflamed).
Hepatitis A: Okužba z virusom hepatitisa A lahko povzroči oteklino jeter (vnetje).
hepatitis B (a viral liver infection);
hepatitisom B (virusno okužbo jeter);
hepatitis B (a viral liver infection);
hepatitisu B (virusni okužbi jeter);
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)
Adsorbirano cepivo proti hepatitisu B (rDNA) z adjuvansom
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)
Adsorbirano rekombinantno cepivo proti hepatitisu B (rDNA) z adjuvansom
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Adsorbirano cepivo proti hepatitisu B (rDNA) z adjuvansom
Hepatitis B and/or C
hepatitis B in/ali C
Hepatitis B and/or hepatitis C virus co-infection
Sočasna okužba z virusom hepatitisa B in/ali z virusom hepatitisa C
Hepatitis B immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs).
Imunoglobulin proti hepatitisu tipa B vsebuje pretežno imunoglobulin G (IgG) s specifično visoko vsebnostjo protiteles proti površinskemu antigenu virusa hepatitisa tipa B (HBs).
Hepatitis B immunoglobulin has no or negligible influence on the ability to drive and use machines.
Immunoglobulin proti hepatitisu tipa B nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
Čim prej po izpostavljenosti (v 24 urah) je treba uporabiti imunoglobulin proti hepatitisu B.
Hepatitis B immunological memory was confirmed in children 4 to 12 years of age.
Imunološki spomin za hepatitis B je bil potrjen pri otrocih od 4. do 12. leta starosti.
Hepatitis B infection and reactivation
okužba s hepatitisom B in reaktivacija
Hepatitis B is a virus that infects the liver causes long term (chronic) infection,and can lead to liver damage.
Virus hepatitisa B je virus, ki okuži jetra, povzroči dolgotrajno (kronično) okužbo in lahko vodi v okvaro jeter.
Hepatitis B reactivation*
reaktivacija hepatitisa B
Hepatitis B reactivation11
reaktivacija hepatitisa B11
Hepatitis B reactivitation
Reaktivacija hepatitisa B
Hepatitis B surface antigen
površinski antigen hepatitisa B
Hepatitis B surface antigen 1, 2, 3 20 micrograms
Površinski antigen virusa hepatitisa B 1, 2, 3 20 mikrogramov
Hepatitis B surface antigen 1, 2, 3 20 micrograms
površinski antigen virusa hepatitisa B1, 2, 3 20 mikrogramov
Hepatitis B surface antigen3,4 10 micrograms
Površinski antigen virusa hepatitisa B3,4 10 mikrogramov
Hepatitis B surface antigen3,4 20 micrograms
Površinski antigen virusa hepatitisa B3,4 20 mikrogramov
Hepatitis B surface antigen5 10 micrograms
25 mikrogramov
Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi.
Pri bolnikih s kronično okužbo z virusom hepatitisa B (HBV), ki so jemali zdravilo Jakavi, so poročali o povečanju virusnega bremena (titra HBV-DNA) skupaj z zvišanjem vrednosti alanin- aminotransferaze in aspartat-aminotransferaze ali brez navedenega zvišanja.
Hepatitis B virus (HBV) antiviral agents
Protivirusna zdravila za zdravljenje hepatitisa B (HBV)
Hepatitis B Virus (HBV) co-infection
Sočasna okužba z virusom hepatitisa B (HBV)
Hepatitis B virus (HBV) infection and reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, has occurred in patients treated with drugs classified as CD20-directed cytolytic antibodies, including Arzerra.
Pri bolnikih, zdravljenih z zdravili, ki se uvrščajo med citolitična protitelesa, usmerjena proti CD20 (vključno z zdravilom Arzerra), se je pojavila okužba z virusom hepatitisa B (HBV) ali njena reaktivacija, v nekaterih primerih s posledičnim fulminantnim hepatitisom, odpovedjo jeter in smrtjo.
Hepatitis B Virus (HBV) reactivation and infection
Reaktivacija in okužba z virusom hepatitisa B (HBV)
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with anti-CD20 antibodies including Gazyvaro (see section 4.8).
Bolnikom, zdravljenim s protitelesi proti CD20 (vključno z zdravilom Gazyvaro), se lahko pojavi reaktivacija virusa hepatitisa B (HBV), v nekaterih primerih s posledičnim fulminantnim hepatitisom, jetrno odpovedjo in smrtjo.
Hepatitis B virus surface antigen, recombinant (HBsAg) * ...................
Rekombinantni površinski antigen virusa hepatitisa B (HBsAg) * ..................
Hepatitis B virus surface antigen, recombinant (HBsAg) * ....................
Rekombinantni površinski antigen virusa hepatitisa B (HBsAg) * ..................
Hepatitis B, Infection*, Bronchopneumonia
okužba z virusom hepatitisa B*, bronhopnevmonija
Hepatitis B: Approximately one quarter of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate, most of which are mild.
Hepatitis B: Neželeni učinki so za pričakovati pri približno 1/4 bolnikov, zdravljenih z dizoproksiltenofovirijevim fumaratom, od katerih jih je večina blaga.
Hepatitis B: Infection with the hepatitis B virus may cause the liver to become swollen (inflamed).
Hepatitis B: Okužba z virusom hepatitisa B lahko povzroči oteklino jeter (vnetje).
Hepatitis B: Tell your doctor if you have or have ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before you begin treatment with Benepali.
Hepatitis B: Če ste kdaj imeli hepatitis B, o tem obvestite svojega zdravnika.
Hepatitis B: Tell your doctor if you or the child have or have ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before you or the child begin treatment with
Hepatitis B: Če ste vi ali vaš otrok kdaj imeli hepatitis B, o tem obvestite zdravnika.
Hepatitis C antivirals
boceprevir:
Hepatitis C antivirals
z lamivudinom (glejte
Hepatitis C antivirals
Zdravila za zdravljenje hepatitisa C
Hepatitis C virus (HCV) antiviral agents
Protivirusna zdravila za zdravljenje hepatitisa C (HCV)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
PROTIVIRUSNA ZDRAVILA Z NEPOSREDNIM DELOVANJEM NA VIRUS HEPATITISA C (HCV)
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are co- administered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see section 4.3 and 4.5).
Protivirusna zdravila proti virusu hepatitisa C (HCV) z neposrednim delovanjem: Če so sočasno s fosamprenavirjem/ritonavirjem uporabljena protivirusna zdravila proti virusu hepatitisa C z neposrednim delovanjem (DAA - direct-acting antivirals), ki se presnavljajo s CYP3A4 ali so induktorji/zaviralci CYP3A4, se zaradi zavrtja ali indukcije encimske aktivnosti CYP3A4 pričakuje spremenjena koncentracija zdravil v plazmi (glejte poglavji 4.3 in 4.5).
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are co- administered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see sections 4.3 and 4.5).
Protivirusna zdravila proti virusu hepatitisa C (HCV) z neposrednim delovanjem: Če so sočasno s fosamprenavirjem/ritonavirjem uporabljena protivirusna zdravila proti virusu hepatitisa C z neposrednim delovanjem (DAA - direct-acting antivirals), ki se presnavljajo s CYP3A4 ali so induktorji/zaviralci CYP3A4, se zaradi zavrtja ali indukcije encimske aktivnosti CYP3A4 pričakuje spremenjena koncentracija zdravil v plazmi (glejte poglavji 4.3 in 4.5).
Hepatitis C: Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
. Hepatitis C: Povejte zdravniku, če ima vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom Enbrel za primer, če bi se okužba poslabšala.
Hepatitis C: Tell your doctor if you have hepatitis C. Your doctor may wish to monitor the treatment with Benepali in case the infection worsens.
Hepatitis C: Povejte zdravniku, če imate hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom Benepali za primer, če bi se okužba poslabšala.
Hepatitis C: Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
Hepatitis C: Povejte zdravniku, če imate vi ali vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom Enbrel za primer, če bi se okužba poslabšala.
hepatitis cholestatic
holestatični hepatitis
Hepatitis Cvirus (HCV) antiviral agents
Protivirusna zdravila za zdravljenje hepatitisa C (HCV)
Hepatitis Hepatitis acute Jaundice Hepatic necrosis Hepatorenal syndrome
hepatitis akutni hepatitis zlatenica nekroza jeter hepatorenalni sindrom
Hepatitis including AST, ALT and GGT increases
hepatitis, vključno s povišanjem AST, ALT in GGT
Hepatitis led to discontinuation of pembrolizumab in 6 (0.2%) patients.
Hepatitis je povzročil ukinitev zdravljenja s pembrolizumabom pri 6 bolnikih (0,2 %).
hepatitis patients who have liver cirrhosis (scarring) that is causing symptoms or who have recently received medicines that affect the immune system,
bolnikih s hepatitisom, ki imajo cirozo jeter, ki povzroča simptome, ali ki so nedavno prejemali zdravila, ki vplivajo na imunski sistem,
hepatitis reactivation of hepatitis B1)
hepatitis reaktivacija hepatitisa B1)
hepatitis reactivation of hepatitis B1) autoimmune hepatitis1)
hepatitis reaktivacija hepatitisa B1) avtoimunski hepatitis1)
Hepatitis resolved in 15 patients.
Izzvenel je pri 15 bolnikih.
Hepatitis toxic, hepatic failure, hepatic cirrhosis, blood alkaline phosphatase increased
toksični hepatitis, odpoved jeter, ciroza jeter, zvišanje alkalne fosfataze v krvi
Hepatitis with mainly cholestatic features (see section 4.4)
hepatitis s prevladujočimi znaki holestaze (glejte poglavje 4.4)
hepatitis with or without jaundice
hepatitis z zlatenico ali brez nje
hepatitis*, cytolytic hepatitis*
hepatitis*, citolitični hepatitis
Hepatitis, abnormal liver function
Hepatitis, nenormalno delovanje jeter
hepatitis, cholecystitis, cholestasis
hepatitis, vnetje žolčnika, holestaza
Hepatitis, cholelithiasis
hepatitis, žolčni kamni
hepatitis, cholelithiasisa, cholestasisa
hepatitis, holelitiazaa, holestazaa
Hepatitis, elevated liver function tests
hepatitis, zvišani jetrni funkcijski testi
Hepatitis, hepatic failure jaundice
hepatitis, jetrna odpoved, zlatenica
hepatitis, hepatic steatosis, hepatitis alcoholic, hepatic failure
hepatitis, jetrna steatoza, alkoholni hepatitis, odpoved jeter
hepatitis, hepatic steatosis, hepatitis alcoholic, hepatic failure
hepatitis, steatoza jeter, alkoholni hepatitis, odpoved jeter
Hepatitis, jaundice
hepatitis, zlatenica
hepatitis, jaundice, hepatic enzyme elevations (mostly consistent with cholestasis)
hepatitis, zlatenica, povečanje jetrnih encimov (večinoma se ujema s holestazo)
Hepatitis, jaundice, hepatic enzymes increased (mostly consistent with cholestasis)
hepatitis, ikterus, zvišane vrednosti jetrnih encimov (večinoma v povezavi z zastojem žolča)
Hepatitis, jaundice, hyperbilirubinaemia
hepatitis, zlatenica, hiperbilirubinemija
Hepatitis/jaundice Hepatic failure
hepatitis/zlatenica jetrna odpoved
Hepatitis/jaundice Hepatic failure
jetrna odpoved
Hepatitis3
odpoved jeter6 zlatenica6
hepatitis; reactivation of hepatitis B;
hepatitis; reaktivacija hepatitisa B;
hepatitis; reactivation of hepatitis B;
hepatitis; reaktivcija hepatitisa B;
Hepatitis§ Urticaria§ Erythema§ Pruritus§
vulvovaginalno srbenje
Hepato biliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepato- biliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepato-biliary
Jetra, žolčnik in žolčevodi
Hepato-biliary disorders
Bolezni jeter in žolčevodov
Hepato-biliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepato-biliary disorders :
Bolezni jeter, žolčnika in žolčevodov:
Hepato-biliary disorders*
Bolezni jeter, žolčnika in
Hepato-biliary disorders*
Bolezni jeter, žolčnika in žolčevodov
Hepato-biliary disorders:
Bolezni jeter, žolčnika in žolčevodov
Hepato-biliary disorders:
Bolezni jeter, žolčnika in žolčevodov:
Hepato-biliary events
Dogodki na jetrih, žolčniku in žolčevodih
Hepatobiliary
Bolezni
Hepatobiliary
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorder
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorders
Bolezni jeter,
Hepatobiliary disorders
Bolezni jeter, ţolčnika in ţolčevodov
Hepatobiliary Disorders
Bolezni jeter, žolčnika in
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevod ov
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevoda
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodo v
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodov Pogostnost neznana:
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodov:
Hepatobiliary disorders
Bolezni jeter, žolčnika in žolčevodovs
Hepatobiliary disorders
Bolezni mišično- skeletnega sistema in vezivnega tkiva
Hepatobiliary disorders
Bolezni prebavil
Hepatobiliary disorders
Bolezni sečil
Hepatobiliary disorders
ekhimoza
Hepatobiliary disorders
kontuzija
Hepatobiliary disorders
Motnje hepatobiliarnega trakta
Hepatobiliary disorders
Očesne bolezni
Hepatobiliary disorders
Plodnost, nosečnost in dojenje
Hepatobiliary disorders
Pogostnost
Hepatobiliary disorders
Presnovne in prehranske motnje
Hepatobiliary disorders
Splošne težave in spremembe na mestu aplikacije
Hepatobiliary disorders
Žilne bolezni
Hepatobiliary disorders
žolčnika in
Hepatobiliary disorders Abnormal liver function tests
Bolezni jeter, žolčnika in žolčevodov Nenormalni testi jetrne funkcije.
Hepatobiliary disorders Common Liver function test abnormal (including transaminases increased)
Bolezni jeter, žolčnika in žolčevodov pogosti nenormalni izvidi testov jetrne funkcije (vključno z zvišanjem transaminaz)
Hepatobiliary disorders*
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorders6
Bolezni jeter, žolčnika in žolčevodov6
Hepatobiliary disorders9
Bolezni jeter, žolčnika in žolčevodov9
Hepatobiliary disorders:
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary disorders:
Bolezni jeter, žolčnika in žolčevodov:
Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (≥ 1/10,000 to < 1/1,000)).
Bolezni jeter, žolčnika in žolčevodov: holestaza, hepatitis (vključno s hepatocelularno poškodbo (glede na zbrane podatke iz preskušanj III. faze so se ti dogodki pojavili redko (≥ 1/10.000 do
Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (≥ 1/10,000 to < 1/1,000)).
Bolezni jeter, žolčnika in žolčevodov: holestaza, hepatitis (vključno s hepatocelularno poškodbo) (glede na zbrane podatke iz preskušanj III. faze so se ti dogodki pojavili redko (≥ 1/10.000 do
Hepatobiliary Disorders: Hepatic decompensation, hepatic failure have been observed during treatment with Exviera with ombitasvir/paritaprevir/ritonavir, with or without ribavirin (see section 4.4).
Bolezni jeter, žolčnika in žolčevodov: med zdravljenjem z zdravilom Exviera z ombitasvirjem/paritaprevirjem/ritonavirjem z ali brez ribavarina so opazili dekompenzacijo jeter in okvaro jeter (glejte poglavje 4.4).
Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)
Neznana pogostnost: zlatenica (intrahepatska holestatska zlatenica)
Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)
Neznana: zlatenica (intrahepatska holestatska zlatenica)
Hepatobiliary disordesrs
Bolezni jeter, žolčnika in žolčevodov
Hepatobiliary events
Dogodki v zvezi z jetri, žolčnikom in žolčevodi
Hepatobiliary events
Pojavi na jetrih, žolčniku in žolčevodih
Hepatobiliary events
Sopojavi na jetrih, žolčniku in žolčevodih
Hepatobiliary system
bolezni jeter, žolčnika in žolčevodov
Hepatobiliary tract
Hepatobiliarni trakt
Hepatobililary disorders
Bolezni jeter, žolčnika in žolčevodov
Hepatobilliary disorders
Bolezni jeter, žolčnika in žolčevodov
hepatocellular carcinoma (11 April 2006)
hepatocelularni karcinom (11. april 2006)
hepatocellular carcinoma (a type of liver cancer);
hepatocelularnim karcinomom (vrsto jetrnega raka);
Hepatocellular damage
hepatocelularna poškodba
hepatocellular damage and hepatitis, cholestasis and jaundice
celic in hepatitis, holestaza in zlatenica
hepatocellular damage including fatal cases (see section 4.4)
hepatocelular ne okvare, vključno s smrtnimi primeri (glejte poglavje 4.4)
hepatocellular damage including fatal cases (see section 4.4)
hepatocelularne okvare, vključno s smrtnimi primeri (glejte poglavje 4.4)
hepatocellular damage, hepatitis, jaundice, hepatomegaly,
okvara jetrnih celic, hepatitis, zlatenica, hepatomegalija,
Hepatocellular injury
hepatocelularna poškodba
Hepatocellular Injury
hiperhidroza
Hepatocellular injury, in rare cases with fatal outcome* (see section 4.4)
hepatocelularne poškodbe, v redkih primerih s smrtim izzidom* (glejte poglavje 4.4)
Hepatocellular injury; Jaundice; Hepatocellular failure
okvara jeter, zlatenica, odpoved jeter
Hepatocellular liver injury, including life-threatening acute liver failure (see section 4.4)
hepatocelularna okvara jeter, vključno s smrtno nevarno akutno odpovedjo jeter (glejte poglavje 4.4)